Ivonescimab (PD-1 × VEGF) has now reported an OS benefit over durvalumab + chemo in the Ph3 HARMONi-GI1 trial in advanced biliary cancer. Will this translate to mUC? HARMONi-GU1 will compare ivonescimab + EV vs EVP 👇🏼 smmttx.com/news/press-releas… @OncoAlert